Organigram Global (OGI) Non Operating Investment Income (2018 - 2026)
Organigram Global (OGI) posted quarterly Non Operating Investment Income of -$28.4 million for Q1 2026, up 13.65% year-on-year from -$25.0 million in Q1 2025, and down 62.24% on a QoQ basis from -$17.5 million in Q4 2025.
Organigram Global (OGI) Non Operating Investment Income (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Non Operating Investment Income for 6 consecutive years, with -$28.4 million the latest figure, recorded in Q1 2026.
- Quarterly Non Operating Investment Income rose 13.65% year-over-year to -$28.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.4 million (down 448.79% YoY) and the FY2025 annual result came in at -$6539.7, down 101.41% from the prior year.
- Non Operating Investment Income declined to -$28.4 million in Q1 2026 per OGI's latest filing, from -$17.5 million in the prior quarter.
- Over the last five years, Non Operating Investment Income for OGI reached as high as $10.4 million in Q4 2024 and fell as low as -$32.9 million in Q1 2025.
- A 4-year average of -$13.6 million and a median of -$17.5 million in 2025 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2025 — Non Operating Investment Income plunged 268.57% — and 2026, when it increased 13.65%.
- Year by year, Non Operating Investment Income stood at $237951.8 in 2023, then jumped by 4260.64% to $10.4 million in 2024, then tumbled by 268.57% to -$17.5 million in 2025, then sank by 62.24% to -$28.4 million in 2026.
- According to Business Quant data, Non Operating Investment Income over the past three periods registered -$28.4 million, -$17.5 million, and -$32.9 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Organigram Global | 121.15 Mn | 154.23 Mn | 28.97 Mn | -28.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.38 Mn |
| Mar 31, 2026 | -28.38 Mn |
| Dec 31, 2025 | -17.49 Mn |
| Dec 31, 2025 | -17.49 Mn |
| Mar 31, 2025 | -32.86 Mn |
| Mar 31, 2025 | -32.86 Mn |
| Dec 31, 2024 | 10.38 Mn |
| Dec 31, 2024 | 10.38 Mn |
| Sep 30, 2023 | 237,951.82 |
| Sep 30, 2023 | 237,951.82 |
| Feb 28, 2021 | 42.33 Mn |
| Feb 28, 2021 | 42.33 Mn |
| Nov 30, 2018 | -246,000.00 |
| Nov 30, 2018 | -246,000.00 |